

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED** **華康生物醫學控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8622)**

### **CHANGE OF COMPLIANCE ADVISER**

The board (the “**Board**”) of directors (the “**Directors**”) of HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED (the “**Company**”) announces that the Company and RHB Capital Hong Kong Limited (“**RHBC**”) have mutually agreed to terminate the compliance adviser agreement entered into between the Company and RHBC dated 25 September 2017, with effect from 31 May 2019 (the “**Termination**”) due to the recent changes in personnel of RHBC. Save as disclosed in this announcement, the Board confirms that, as at the date of this announcement, there are no other matters relating to the Termination that need to be drawn to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board further announces that Ever-Long Securities Company Limited (“**Ever-Long**”) has been appointed as the new compliance adviser to the Company as required pursuant to Rule 6A.27 of The Rules Governing the Listing of Securities on the GEM of Stock Exchange (the “**GEM Listing Rules**”) with effect from 31 May 2019. The Company initially listed on the GEM of the Stock Exchange on 13 December 2018. Accordingly, the term of engagement with Ever-Long shall be until the date, pursuant to Rule 6A.19 of the GEM Listing Rules, on which financial results of the Company for the second full financial year commencing after the date of initial listing of the Company (being the financial year ending 31 December 2020), or until the compliance adviser agreement entered into between the Company and Ever-Long is terminated in accordance with its terms, whichever is earlier.

Ever-Long is a licensed corporation permitted to carry out type 1 (dealing in securities), type 4 (advising on securities) and type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

By Order of the Board  
**HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**  
**ZHANG Shuguang**  
*Chairman and Executive Director*

Hong Kong, 31 May 2019

*As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael and the Independent Non-executive Directors are Dr. Yeung David Wai Chow, Mr. Kwok Chi Shing and Mr. Chan Kin Sang.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven days after the date of publication and on the Company’s website at [www.szhuakang.com](http://www.szhuakang.com).*